Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease

Journal of Neural Transmission

Volumn 117, Issue 12, 2010, Pages 1337-1351

  Moreira, Eduardo L G ^a   Rial, Daniel ^a   Aguiar Jr , Aderbal S ^a   Figueiredo, Cláudia P ^a   Siqueira, Jarbas M ^a   Dalbó, Silvia ^a   Horst, Heros ^a   De Oliveira, Jade ^a   Mancini, Gianni ^a   Dos Santos, Tiago S ^a   Villarinho, Jardel G ^b   Pinheiro, Francielle V ^b   Marino Neto, José ^a   Ferreira, Juliano ^b   De Bem, Andreza F ^a   Latini, Alexandra ^a   Pizzolatti, Moacir G ^a   Ribeiro Do Valle, Rosa M ^a   Prediger, Rui D S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Behavior; Catechin; Croton celtidifolius; Intranasal; MPTP; Neuroprotection; Parkinson's disease; Proanthocyanidin; Rat

Indexed keywords

CATECHIN; CATECHIN(4ALPHA-8)CATECHIN; CROTON CELTIDIFOLIUS EXTRACT; EPICATECHIN; GALLOCATECHIN; GALLOCATECHIN(4ALPHA-8)CATECHIN; PLANT EXTRACT; PROANTHOCYANIDIN DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CROTON CELTIDIFOLIUS; DEPRESSION; LOCOMOTION; MALE; MEDICINAL PLANT; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; OLFACTORY BULB; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

ADMINISTRATION, INTRANASAL; ANIMALS; CROTON; DISEASE MODELS, ANIMAL; MALE; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PLANT EXTRACTS; PROANTHOCYANIDINS; RATS; RATS, WISTAR;

EID: 78651237799     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0464-x     Document Type: Article

References (82)

1. N Adachi S Tomonaga T Tachibana DM Denbow M Furuse 2006 (-)-Epigallocatechin gallate attenuates acute stress responses through gabaergic system in the brain Eur J Pharmacol 531 171 175 1:CAS:528:DC%2BD28Xhtlejt7c%3D
2. H Allain D Bentué-Ferrer Y Akwa 2008 Disease-modifying drugs and Parkinson's disease Prog Neurobiol 84 25 39 1:CAS:528:DC%2BD2sXhsVOrtb7J
3. J Archer 1973 Tests for emotionality in rats and mice: a review Anim Behav 21 205 235 1:STN:280:DyaE3s3is12qtg%3D%3D
4. MJ Balunas AD Kinghorn 2005 Drug discovery from medicinal plants Life Sci 78 431 441 1:CAS:528:DC%2BD2MXht1ejsrbP
5. MF Beal 2001 Experimental models of Parkinson's disease Nat Rev Neurosci 2 325 334 1:CAS:528:DC%2BD3MXjs1Ogtrs%3D
6. H Braak E Ghebremedhin U Rub H Bratzke K Del Tredici 2004 Stages in the development of Parkinson's disease-related pathology Cell Tissue Res 318 121 134
7. A Cassina R Radi 1996 Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport Arch Biochem Biophys 328 309 316 1:CAS:528:DyaK28Xit1Klt7w%3D
8. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5:235-245
9. R Coopersmith FB Weihmuller CL Kirstein JF Marshall M Leon 1991 Extracellular dopamine increases in the neonatal olfactory bulb during odor preference training Brain Res 564 149 153 1:STN:280:DyaK387js1Witw%3D%3D
10. V Crespy G Williamson 2004 A review of the health effects of green tea catechins in in vivo animal models J Nutr 134 3431 3440
11. JL Cummings DL Masterman 1999 Depression in patients with Parkinson's disease Int J Geriatr Psychiatry 14 711 718 1:STN:280:DyaK1MvhtVKntg%3D%3D
12. Da Cunha C, Gevaerd MS, Vital MA, Miyoshi E, Andreatini R, Silveira R, Takahashi RN, Canteras NS (2001) Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 124(1):9-18
13. S DalBó S Jurgensen H Horst AA Ruzza DN Soethe AR Santos MG Pizzolatti RM Ribeiro-do-Valle 2005 Antinociceptive effect of proanthocyanidins from Croton celtidifolius bark J Pharm Pharmacol 57 765 771
14. S DalBó S Jurgensen H Horst DN Soethe AR Santos MG Pizzolatti RM Ribeiro-do-Valle 2006 Analysis of the antinociceptive effect of the proanthocyanidin-rich fraction obtained from Croton celtidifolius barks: evidence for a role of the dopaminergic system Pharmacol Biochem Behav 85 317 323
15. S DalBó EG Moreira FC Brandão H Horst MG Pizzolatti GA Micke RM Ribeiro-do-Valle 2008 Mechanisms underlying the vasorelaxant effect induced by proanthocyanidin-rich fraction from Croton celtidifolius in rat small resistance arteries J Pharmacol Sci 106 234 241
16. R Dantzer RM Bluthe GF Koob M Le Moal 1987 Modulation of social memory in male rats by neurohypophyseal peptides Psychopharmacology 91 363 368 1:CAS:528:DyaL2sXhsV2rtbk%3D
17. TM Dawson 2000 New animal models for Parkinson's disease Cell 101 115 118 1:CAS:528:DC%2BD3cXislKjur8%3D
18. TM Dawson VL Dawson 2002 Neuroprotective and neurorestorative strategies for Parkinson's disease Nat Neurosci 5 1058 1061 1:CAS:528:DC%2BD38Xpt1entb0%3D
19. TM Dawson VL Dawson 2003 Molecular pathways of neurodegeneration in Parkinson's disease Science 302 819 822 1:CAS:528:DC%2BD3sXos1Cmt7w%3D
20. V Di Matteo E Esposito 2003 Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis Curr Drug Targets CNS Neurol Disord 2 95 107 1:CAS:528:DC%2BD3sXislOntro%3D
21. DE Dluzen G Kefalas 1996 The effects of intranasal infusion of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice Brain Res 741 215 219 1:CAS:528:DyaK28XmvFaktro%3D
22. DE Dluzen ID Kreutzberg 1993 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) disrupts social memory/recognition processes in the male mouse Brain Res 609 98 102 1:CAS:528:DyaK3sXktVaks7o%3D
23. RL Doty DA Deems S Stellar 1988 Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration Neurology 38 1237 1244 1:STN:280:DyaL1c3ovVKlug%3D%3D
24. RL Doty SM Bromley MB Stern 1995 Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria Neurodegeneration 4 93 97 1:STN:280:DyaK2MzitlGlsw%3D%3D
25. MM Ferro MI Bellissimo JA Anselmo-Franci ME Angellucci NS Canteras C Da Cunha 2005 Comparison of bilaterally 6-OHDA and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations J Neurosci Methods 148 78 87 1:CAS:528:DC%2BD2MXhtVynt7rM
26. Finberg JP, Wang J, Bankiewicz K, Harvey-White J, Kopin IJ, Goldstein DS (1998) Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl 52:279-285
27. J Franco RD Prediger P Pandolfo RN Takahashi M Farina AL Dafre 2007 Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb Life Sci 80 1906 1914 1:CAS:528:DC%2BD2sXktF2rsL4%3D
28. J Fukae Y Mizuno N Hattori 2007 Mitochondrial dysfunction in Parkinson's disease Mitochondrion 7 58 62 1:CAS:528:DC%2BD2sXisl2rsbY%3D
29. M Gassen Y Glinka B Pinchasi MB Youdim 1996 Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction Eur J Pharmacol 308 219 225 1:CAS:528:DyaK28Xkt12rtb0%3D
30. M Gerlach P Riederer 1996 Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man J Neural Transm 103 987 1041 1:CAS:528:DyaK28XntVKku7Y%3D
31. M Gerlach P Foley P Riederer 2003 The relevance of preclinical studies for the treatment of Parkinson's disease J Neurol 250 31 34
32. MS Gevaerd RN Takahashi R Silveira C Da Cunha 2001 Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats Brain Res Bull 55 101 106 1:CAS:528:DC%2BD3MXks1OltL4%3D
33. Gökhan-Kelekçi N, Yabanoǧlu S, Küpeli E, Salgin U, Ozgen O, Uçar G, Yeşilada E, Kendi E, Yeşilada A, Bilgin AA (2007) A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Bioorg Med Chem 15(17):5775-5786
34. WP Goldman JD Baty VD Buckles S Sahrmann JC Morris 1998 Cognitive and motor functioning in Parkinson's disease-subjects with and without questionable dementia Arch Neurol 55 674 680 1:STN:280:DyaK1c3ms1Olsw%3D%3D
35. LN Grinberg H Newmark N Kitrossky E Rahamim M Chevion EA Rachmilewitz 1997 Protective effects of tea polyphenols against oxidative damage to red blood cells Biochem Pharmacol 54 973 978 1:CAS:528:DyaK2sXntFelt70%3D
36. +)-analogs on the respiratory chain of bovine heart mitochondria Arch Biochem Biophys 337 69 74 1:CAS:528:DyaK2sXktlaisA%3D%3D
37. RE Heikkila L Manzino FS Cabbat RC Duvoisin 1984 Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors Nature 311 467 469 1:CAS:528:DyaL2cXmtVGmuro%3D
38. C Henchcliffe MF Beal 2008 Mitochondrial biology and oxidative stress in Parkinson's disease pathogenesis Nat Clin Pract Neurol 4 600 609 1:CAS:528:DC%2BD1cXhtlWktbnM
39. EC Hirsch S Hunot 2009 Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8 382 397 1:CAS:528:DC%2BD1MXks1Sis70%3D
40. JW Langston 1996 The etiology of Parkinson's disease with emphasis on the MPTP story Neurology 47 153 160
41. A Latini M Rodriguez R Borba Rosa K Scussiato G Leipnitz D Reis de Assis G Da Costa Ferreira C Funchal MC Jacques-Silva L Buzin R Giugliani A Cassina R Radi M Wajner 2005 3-Hydroxyglutaric acid moderately impairs energy metabolism in brain of young rats Neuroscience 135 111 120 1:CAS:528:DC%2BD2MXpslCntrw%3D (Pubitemid 41219742)
42. Y Levites O Weinreb G Maor MB Youdim S Mandel 2001 Green tea polyphenol (-)-epigallocatechin-3-gallate prevents n-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration J Neurochem 78 1073 1082 1:CAS:528:DC%2BD3MXms12rs7w%3D
43. Y Levites T Amit S Mandel MB Youdim 2003 Neuroprotection and neurorescue against abeta toxicity and pkc-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate FASEB J 17 952 954 1:CAS:528:DC%2BD3sXjsFakt74%3D
44. A Lieberman 2006 Depression in Parkinson's disease: a review Acta Neurol Scand 113 1 8 1:CAS:528:DC%2BD28XislKhtrw%3D
45. GB Mahady 2001 Global harmonization of herbal health claims J Nutr 131 1120 1123
46. S Mandel MB Youdim 2004 Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases Free Radic Biol Med 37 304 317 1:CAS:528:DC%2BD2cXltF2rsbY%3D
47. SA Mandel T Amit L Kalfon L Reznichenko MB Youdim 2008 Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins J Nutr 138 1578 1583
48. T Matsumoto O Suzuki T Furuta M Asai Y Kurokawa Y Nimura Y Katsumata I Takahashi 1985 A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate Clin Biochem 18 126 129 1:CAS:528:DyaL2MXltVSksr4%3D
49. R Mayeux 1990 The "serotonin hypothesis" for depression in Parkinson's disease Adv Neurol 53 163 166 1:STN:280:DyaK3M%2FltVymtw%3D%3D
50. R Mayeux 2003 Epidemiology of neurodegeneration Annu Rev Neurosci 26 81 104 1:CAS:528:DC%2BD3sXntFSis7k%3D
51. W Meissner MO Hill F Tison CE Gross E Bezard 2004 Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials Trends Pharmacol Sci 25 249 253 1:CAS:528:DC%2BD2cXjs1Cnurc%3D
52. E Miyoshi S Wietzikoski M Camplessei R Silveira RN Takahashi C Da Cunha 2002 Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions Brain Res Bull 58 41 47 1:CAS:528:DC%2BD38Xlt12ktLY%3D
53. EL Moreira D Rial FS Duarte CR de Carvalho H Horst MG Pizzolatti RD Prediger RM Ribeiro-do-Valle 2010 Central nervous system activity of the proanthocyanidin-rich fraction obtained from Croton celtidifolius in rats J Pharm Pharmacol 62 1061 1068 1:CAS:528:DC%2BC3cXhtVeis7nE
54. GM Nardi R Felippi S DalBó JM Siqueira-Junior DC Arruda F Delle Monache AK Timbola MG Pizzolatti K Ckless RM Ribeiro-do-Valle 2003 Anti-inflammatory and antioxidant effects of Croton celtidifolius bark Phytomedicine 10 176 184 1:STN:280:DC%2BD3s3gsFaqtA%3D%3D (Pubitemid 36433214)
55. GM Nardi JM Siqueira-Junior F Delle Monache MG Pizzolatti K Ckless RM Ribeiro-do-Valle 2007 Antioxidant and anti-inflammatory effects of products from Croton celtidifolius Bailon on carrageenan-induced pleurisy in rats Phytomedicine 14 115 122 1:CAS:528:DC%2BD2sXktleisb0%3D
56. +-induced dopamine neuron injury Life Sci 72 1073 1083 1:CAS:528:DC%2BD38XpsFWht74%3D
57. Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates, 5th edn. Academic Press, San Diego, p 205
58. RD Porsolt G Anton N Blavet M Jalfre 1978 Behavioural despair in rats: a new model sensitive to antidepressant treatments Eur J Pharmacol 47 379 391 1:CAS:528:DyaE1cXhvVagsr0%3D
59. RD Prediger LC Batista E Miyoshi RN Takahashi 2004 Facilitation of short-term social memory by ethanol in rats is mediated by dopaminergic receptors Behav Brain Res 153 149 157 1:CAS:528:DC%2BD2cXlt1WgsL0%3D
60. RD Prediger C Da Cunha RN Takahashi 2005 Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpine-treated rats Behav Pharmacol 16 209 218 1:CAS:528: DC%2BD2MXlt1Smtro%3D
61. RD Prediger LC Batista R Medeiros P Pandolfo JC Florio RN Takahashi 2006 The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease Exp Neurol 202 391 403 1:CAS:528:DC%2BD28Xht1Shur7P
62. RD Prediger D Rial R Medeiros CP Figueiredo RL Doty RN Takahashi 2009 An intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease Ann N Y Acad Sci 1170 629 636 1:CAS:528:DC%2BD1MXhtFSqsLfL
63. RD Prediger AS Aguiar Jr AE Rojas-Mayorquin CP Figueiredo FC Matheus L Ginestet C Chevarin ED Bel R Mongeau M Hamon L Lanfumey R Raisman-Vozari 2010 Single intranasal administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease Neurotoxic Res 17 115 129
64. S Przedborski K Tieu C Perier M Vila 2004 MPTP as a mitochondrial neurotoxic model of Parkinson's disease J Bioenerg Biomembr 36 375 379 1:CAS:528:DC%2BD2cXnsFyjtbc%3D
65. C Ramassamy 2006 Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets Eur J Pharmacol 545 51 64 1:CAS:528:DC%2BD28XotlWkur8%3D
66. IH Richard S Frank MP Mcdermott H Wang AW Justus KA Ladonna R Kurlan 2004 The ups and downs Parkinson's disease: a prospective study of mood and anxiety fluctuations Cogn Behav Neurol 17 201 207
67. P Riederer S Wuketich 1976 Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis J Neural Transm 38 277 301 1:CAS:528:DyaE28XlsVSqtb4%3D
68. S Sant' Anna Gda P Machado PD Sauzem FA Rosa MA Rubin J Ferreira HG Bonacorso N Zanatta MA Martins 2009 Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors Bioorg Med Chem Lett 19 546 549
69. AH Schapira 2008 Mitochondrial dysfunction in neurodegenerative diseases Neurochem Res 33 2502 2509 1:CAS:528:DC%2BD1cXhtlCku77J
70. AH Schapira CW Olanow 2004 Neuroprotection in Parkinson's disease: mysteries, myths and misconceptions JAMA 291 358 364 1:CAS:528: DC%2BD2cXmtlelsg%3D%3D
71. AH Schapira E Bezard J Brotchie F Calon GL Collingridge B Ferger B Hengerer E Hirsch P Jenner N Le Novere JA Obeso MA Schwarzschild U Spampinato G Davidai 2006 Novel pharmacological targets for the treatment of Parkinson's disease Nat Rev Drug Discov 5 845 854 1:CAS:528:DC%2BD28XhtVajsbnE
72. A Schrag 2004 Psychiatric aspects of Parkinson's disease: an update J Neurol 251 795 804
73. EK Schroeder NA Kelsey J Doyle E Breed RJ Bouchard FA Loucks RA Harbison DA Linseman 2009 Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons Antioxid Redox Signal 11 469 480 1:CAS:528:DC%2BD1MXhtFOrtLc%3D
74. Smith LB, Downs RJ, Klein RM (1988) Euforbiaceas. In: Flora ilustrada catarinense. ItajaI, Brazil: Herbário Barbosa. Rodrigues, pp 223-225
75. MT Tadaiesky PA Dombrowski CP Figueiredo E Cargnin-Ferreira C Da Cunha RN Takahashi 2008 Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease Neuroscience 156 830 840 1:CAS:528:DC%2BD1cXhtlSgsrnO
76. E Tolosa Y Compta C Gaig 2007 The premotor phase of Parkinson's disease Parkinsonism Relat Disord 13 2 7
77. Weinreb O, Amit T, Mandel S, Youdim MB (2009) Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr. doi: 10.1007/s12263009014304
78. DA Weldon ML Travis DA Kennedy 1991 Posttraining D1 receptor blockade impairs odor conditioning in neonatal rats Behav Neurosci 105 450 458 1:STN:280:DyaK3MzitFOmtg%3D%3D
79. WR Wu XZ Zhu 1999 Involvement of monoamine oxidase inhibition in neuroprotective and neurorestorative effects of Ginko biloba extract against MPTP-induced nigrostriatal dopaminergic toxicity in C57 mice Life Sci 65 157 164 1:CAS:528:DyaK1MXktFais7w%3D
80. MB Youdim M Fridkin H Zheng 2004 Novel bifunctional drugs targeting monoamine oxidase inhibiton and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases J Neural Transm 111 1455 1471 1:CAS:528:DC%2BD2cXotFCrtbY%3D
81. K Zhao G Luo S Gianelli HH Szeto 2005 Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptoses induced by tert-butyl hydroperoxide in neuronal cell lines Biochem Pharmacol 70 1796 1806 1:CAS:528:DC%2BD2MXht1egs7nI
82. C Zhou Y Huang S Przedborski 2008 Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance Ann N Y Acad Sci 1147 93 104 1:CAS:528:DC%2BD1MXhsVaqtbs%3D